Association Between Peripheral Blood CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients

BACKGROUND. Rituximab is used widely for desensitization in ABO-incompatible and donor-specific antibody-positive kidney transplantation. However, data about the effects of individual differences in rituximab-induced B-cell suppression on antibody-mediated rejection (AMR) remain unknown. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanmoku, Koji, Shinzato, Takahiro, Kubo, Taro, Shimizu, Toshihiro, Yagisawa, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616141/
https://www.ncbi.nlm.nih.gov/pubmed/31334341
http://dx.doi.org/10.1097/TXD.0000000000000907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616141/
https://www.ncbi.nlm.nih.gov/pubmed/31334341
http://dx.doi.org/10.1097/TXD.0000000000000907

Ejemplares similares